explore -WSS

explore

author：hotspot 2025-09-28 01:38:02 - browse：25761

Photo of an arrangement of aspirin pills — Patrick Sison/AP

Low-dose aspirin led to a reduction in liver fat among patients with metabolic-associated liver disease, a small study out of Boston found.

The clinical trial, led by Tracey Simon of Massachusetts General Hospital and Harvard Medical School, compared two groups of patients with metabolic dysfunction-associated steatotic liver disease, or MASLD. One group was given baby aspirin daily for six months, while the other received a placebo pill. At the end of the study period, the aspirin group had reduced hepatic fat content while the placebo group had higher fat buildup.

MASLD (formerly known as non-alcoholic fatty liver disease) is a growing health threat, with 1 in 3 Americans having a troublesome amount of fat in their liver. The lipid buildup feeds into a toxic cycle of inflammation, tissue damage and, ultimately, irreversible scarring.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： New England Journal of Medicine addresses racist history, slavery

WSS

DeSantis can now import cheaper drugs. But will Biden get credit?

JPM pitch from hospitals? Revenue streams outside of patient care

Ascension's ugly legal battle over care for poor patients in Texas

STAT Virtual Event: JPM Recap, Live!

Idaho abortion case may prompt more restrictions in other states

Doulas covered by Medicaid under New York's new plan

focus

explore

focus

Moonlake's readout produced a cash windfall. Risks remain

Risky weight loss products often used by teens globally, per study

State Dept. review finds Biden bears some blame for Afghanistan failures

Nonprofit, backed by Microsoft, to certify AI tools in health care

Trump demands the U.S. pay no more for drugs than other countries … again

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Trump demands the U.S. pay no more for drugs than other countries … again

How I ended up pumping milk in a bathroom stall at JPM 2024

Bright Health sells Medicare Advantage business to Molina

New menopause drug shows promise in relief for hot flashes

hotspot

At JPM 2024, hospital systems pitch financial strength to investors

Readout LOUD podcast: live from JPM 2024

Medicare Advantage coverage denials need scrutiny, senators say

A preacher's new calling: Diversifying neuroscience research

HHS names first

Fauci’s Covid grilling leads GOP to weigh foreign research rules

focus

focus

hotspot

hotspot